Quantification of Stigmasterol in Successive Extracts of Clerodendrum Serratum, Poly Herbal Formulation By Hptlc Method And In-vitro Anti - Oxidant Activity Studies.

The aim of the present study is to carry out the quantification of Clerodendrum serratum containing poly herbal formulations by HPTLC and to study the invitro anti-oxidant activity of nitric oxide scavenging activity of the roots of Clerodendrum serratum.The rhizome part of Clerodendrum serratum has been selected, dried, powdered and extracted with petroleum ether, chloroform, ethyl acetate and methanol successively by continuous hot percolation method using soxhlet apparatus. Preliminary phytochemical screening of the successive extracts showed the presence of chemical constituents like triterpenoids, flavonoids, alkaloids, tannins, glycosides and sesquiterpenes. The Rf value of stigmasterol was found to be 0.80 ± 0.02.The developed methods were validated as per ICH guidelines. The LOD and LOQ was found to be 100 and 300 ng/spot respectively for HPTLC. The anti-oxidant activity was highest in petroleum ether extract when compared to the other extracts by using ascorbic acid as control. This shows that the polyherbal formulation containing stigmasterol has medicinal value and that it may be utillised for its anti-oxidant properties.

Quantitative Estimation of Lupeol in Polyherbal Formulation And Successive Extracts of Crataeva Nurvala and their In-Vitro Anti-Inflammatory Activity Study.

The aim of the present study is to carry out the quantitative estimation of lupeol in poly herbal formulations by HPTLC and to study the invitro antiinflammatory activity study of Crataeva nurvala bark. The bark of Crataeva nurvala was selected, dried, powdered and extracted with petroleum ether, diethyl amine and methanol successively by continuous hot percolation method using soxhlet apparatus. Preliminary phytochemical screening of the successive extracts showed the presence of chemical constituents like triterpenoids, flavonoids, alkaloids, tannins, glycosides and sesquiterpenes. The Rf value of lupeol was found to be 0.49 ± 0.03.The developed methods were validated as per ICH guidelines. The LOD and LOQ was found to be 50 and 300ng/spot respectively for HPTLC. The anti-inflammatory activity was highest in petroleum ether extract when compared to other extracts when evaluated by using ibuprofen as the control. This shows that the polyherbal formulation and medicinal plants containing lupeol as the active constituent has medicinal value and that they may be utillised for their anti-inflammatory properties.

Sunitinib in metastatic renal cell carcimoma: A single-center experience.

INTRODUCTION: Historically, metastatic renal cell carcinoma (RCC) has had poor prognosis; the outcomes have improved with the introduction of tyrosine‑kinase inhibitors, such as sunitinib. There is no reported literature from India on the use of sunitinib in metastatic RCC. We present an analysis of sunitinib at our institute over 4 years. MATERIALS AND METHODS: An unselected population of patients with metastatic or relapsed metastatic RCC receiving sunitinib was analyzed with respect to patient characteristics, response, toxicity, and outcomes. RESULTS: Fifty‑nine patients (51 males, 8 females) with a median age of 55 years were included in the study. Lungs and bones were the most common site of metastases. The patients received a median number of 4 cycles, with 23 patients requiring dose‑modification and 12 discontinuing therapy due to toxicity. Overall, 38 patients (65%) had CR, PR, or standard deviation while 14 had progression or death at initial evaluation. The median progression‑free survival (PFS) was 11.4 months and overall survival was 22.6 months. Hand–foot syndrome, fatigue, mucositis, skin rash, and vomiting were seen more often among our patients, whereas hypertension was not as common compared with previously published reports. CONCLUSION: Sunitinib is a viable option for the treatment of metastatic RCC and shows a comparable PFS in Indian patients. Although toxicity remains a concern, most of the adverse effects can be managed conservatively. Careful patient selection, tailoring the dose of therapy, adequate counseling, and careful follow‑up is essential for optimum therapy.

Insulin oedema: an uncommon complication of insulin therapy.

A 45 year old markedly underweight man presented with polydipsia, polyuria and tingling sensation in both lower limbs of one month duration. Following insulin treatment, he developed gross fluid retention (peripheral oedema and puffiness of face) and a weight gain of 1.8 kg. The oedema occurred on the 3rd day after starting treatment and disappeared on the 7th day without the use of diuretics. Insulin oedema is an uncommon complication of insulin which may occur on introduction of insulin therapy or on increasing the dose, and may be due to the effect of insulin on vascular permeability and renal tubules.